Trials / Completed
CompletedNCT05530291
Incidence and Clinical Burden of Erythropoietin Hyporesponsiveness - a Retrospective Database Analysis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 85,259 (actual)
- Sponsor
- Astellas Pharma Global Development, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study consists of two phases. The purpose of phase 1 is to identify incidence and patterns of erythropoiesis-stimulating agent (ESA) hyporesponsiveness and its associated factors in ESA treated patients. The purpose of phase 2 to identify outcomes associated with ESA hyporesponsiveness. Key aspects of the phase 2 study design will entirely depend on the results from phase 1.
Detailed description
This is a retrospective database analysis of patients with anemia associated with chronic kidney disease (CKD) treated with ESAs from January 1st 2015 - December 31st 2021. Data will be derived from European Clinical Database (EuCliD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non-interventional | Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs |
Timeline
- Start date
- 2022-11-18
- Primary completion
- 2022-11-22
- Completion
- 2022-11-22
- First posted
- 2022-09-07
- Last updated
- 2024-11-07
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05530291. Inclusion in this directory is not an endorsement.